BioSpace News Archive

Bionano Genomics, Inc. (BNGO), today announced the publication in Cancers of a peer-reviewed study from Augusta University on the utility of combining optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for the standard evaluation of myeloid cancers.

Daxor Corporation announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 19 th Annual Meeting from June 29 - July 1, 2023 at the Boston Marriott Copley Place.

SEED Therapeutics, a BeyondSpring subsidiary and global research company focused on harnessing and engineering “molecular glues,” a targeted protein degradation platform to attack previously believed undruggable targets, announced that it has appointed Jackson Tai to its Board of Directors.

Aridis Pharmaceuticals, Inc. today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

Eli Lilly and Company is teaming up with the American Diabetes Association® and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRASG12C inhibitor, demonstrating durable IC activity in patients living with KRASG12C-mutated NSCLC with untreated CNS metastases.

Delix Therapeutics today announced the completion of dosing of the first cohort of subjects in its phase I clinical trial of lead candidate, DLX-001, a non-hallucinogenic psychoplastogen.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease.

DiamiR Biosciences today announced that it will present two posters at the Alzheimer’s Association International Conference (AAIC), taking place July 16 – 20, 2023, in Amsterdam, Netherlands.

Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today announced the results of a new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy (KIT).